Eptinezumab for the prevention of chronic migraine: efficacy and safety through 24 weeks of treatment in the phase 3 PROMISE-2 (Prevention of migraine via intravenous ALD403 safety and efficacy–2) study

• Published in: Journal of headache and pain Vol. 21; no. 1; pp. 120 - 12
• Main Authors: Silberstein, Stephen, Diamond, Merle, Hindiyeh, Nada A., Biondi, David M., Cady, Roger, Hirman, Joe, Allan, Brent, Pederson, Susan, Schaeffler, Barbara, Smith, Jeff
• Format: Journal Article
• Language: English
• Published: Milan Springer Milan 06.10.2020; BMC
• Subjects: Adult; Antibodies, Monoclonal, Humanized; Calcitonin Gene-Related Peptide; Chronic migraine; Double-Blind Method; Efficacy; Eptinezumab; Humans; Internal Medicine; Medicine; Medicine & Public Health; Migraine Disorders - drug therapy; Migraine Disorders - prevention & control; Neurology; Pain Medicine; Research Article; Safety; Treatment Outcome; Chronic migraine; Efficacy; Safety; Eptinezumab

Background PROMISE-2 was a phase 3, randomized, double-blind, placebo-controlled study that evaluated the efficacy and safety of repeat intravenous (IV) doses of the calcitonin gene-related peptide–targeted monoclonal antibody eptinezumab (ALD403) for migraine prevention in adults with chronic migra...